Zura Bio (NASDAQ:ZURA) & Gilead Sciences (NASDAQ:GILD) Critical Analysis

Gilead Sciences (NASDAQ:GILDGet Free Report) and Zura Bio (NASDAQ:ZURAGet Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 15.8% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Gilead Sciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Zura Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gilead Sciences 1.76% 24.34% 8.36%
Zura Bio N/A -64.56% -50.33%

Analyst Recommendations

This is a breakdown of recent recommendations for Gilead Sciences and Zura Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences 0 12 7 0 2.37
Zura Bio 0 0 5 1 3.17

Gilead Sciences currently has a consensus target price of $84.00, suggesting a potential upside of 24.35%. Zura Bio has a consensus target price of $19.75, suggesting a potential upside of 448.61%. Given Zura Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Gilead Sciences and Zura Bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gilead Sciences $27.12 billion 3.10 $5.67 billion $0.36 187.64
Zura Bio N/A N/A -$69.24 million N/A N/A

Gilead Sciences has higher revenue and earnings than Zura Bio.

Summary

Gilead Sciences beats Zura Bio on 8 of the 12 factors compared between the two stocks.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Zura Bio

(Get Free Report)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.